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High dose ursodeoxycholic acid for the treatment of primary
sclerosing cholangitisq
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Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USASee Article, pages 792–800In this issue of the Journal, Cullen and colleagues [1]
explore the eﬀects of three doses of ursodeoxycholic acid
(UDCA) (10, 20 and 30 mg/kg/day) on liver biochemist-
ries, UDCA bile acid enrichment, liver histology, and
Mayo risk score, in 31 patients with primary sclerosing
cholangitis (PSC).
PSC is a chronic cholestatic liver disease of young
adults, frequently associated with inﬂammatory bowel
disease. Even though its course is highly variable, it is
usually slowly progressive and associated with high
morbidity and mortality. Although PSC is an uncom-
mon disease, it is among the most common indications
for liver transplantation in Europe and in the United
States [2]. Multiple drugs have been evaluated in the
treatment of this disease, none of which have been of
convincing beneﬁt.
UDCA has been the drug most widely evaluated in
the treatment of PSC and is the most promising one to
date. Several controlled and uncontrolled studies have
consistently demonstrated that UDCA in a wide dose
range from 10 to 30 mg/kg/day has beneﬁcial eﬀects
on liver biochemistries [3–11]. To date, the relation
between improvement of liver biochemistries and clini-
cally relevant ﬁndings such as the development of cir-
rhosis and it complications, need for liver0168-8278/$34.00  2008 European Association for the Study of the Liver.
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have documented an improvement in liver histology
[3,6,9] and cholangiographic features [9], but these out-
comes have not been evaluated in all studies. Most of
the trials performed to date have been limited by small
numbers of patients and relatively short follow-up peri-
ods, and have not allowed conclusions with regard to
eﬀects on survival free of liver transplantation and over-
all survival. In brief, UDCA has not yet shown deﬁnite
evidence of long-term beneﬁt in PSC.
Earlier studies were conducted using doses between
10 and 15 mg/kg per day, similar to those used in studies
with UDCA in the treatment for primary biliary cirrho-
sis (PBC). The largest placebo-controlled study using
UDCA in this dose range, in which 51 patients with
PSC received doses of UDCA between 13 and 15 mg/
kg per day, showed beneﬁcial eﬀects limited to liver bio-
chemistries, but no diﬀerence in other outcomes when
compared to the placebo group after as much as 6 years
of follow-up [4].
Higher doses of UDCA have been studied in chole-
static liver diseases. When three doses of UDCA were
compared in patients with PBC, the daily dose of 13–
15 mg/day was associated with similar biochemical and
Mayo risk score improvement and UDCA bile acid
enrichment when compared to higher doses of 23–
25 mg/kg [12]. In cystic ﬁbrosis, improvement in liver
biochemistries has been demonstrated with treatment
with doses of 10–15 mg/kg [13,14], but, in contrast to
PBC, dose–response studies have demonstrated that
higher doses are more eﬃcacious in improving liver bio-
chemistries and UDCA bile enrichment [15].
Doses greater than 20 mg/kg per day of UDCA may
also be more eﬀective than lower doses in PSC. In anPublished by Elsevier B.V. All rights reserved.
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dose (25–30 mg/kg per day) UDCA, and substantial
reduction not only in liver biochemistries but also Mayo
risk score was observed after 12 months of therapy (10).
An independent, double-blind, placebo-controlled trial
of UDCA at 20 mg/kg per day involving 102 patients
observed improvement in liver biochemistries, liver his-
tology and cholangiographic appearance after 2 years
of therapy, but not on survival [9]. No signiﬁcant
UDCA-related adverse events were reported from any
of these studies. In the largest study of high dose UDCA
reported to date, 219 patients were randomised to
receive either high dose UDCA (17–23 mg/kg per day)
or placebo for 5 years. In contrast to previous studies,
no signiﬁcant decrease of serum alkaline phosphatase
was observed in the 97 UDCA-treated patients, suggest-
ing suboptimal patient compliance to UDCA [16]. The
authors conclude there was no signiﬁcant beneﬁt from
high dose UDCA on survival free of liver transplanta-
tion. Of note, the study protocol included a hard to
achieve main endpoint (greater than 50% reduction in
survival free of liver transplantation in 5 years) and
the study was closed after fewer than 2/3 of patients in
the estimated sample size were enrolled, resulting in an
ultimately underpowered study to demonstrate signiﬁ-
cant diﬀerence in survival free of transplantation
between the treatment arms.
The biliary enrichment of UDCA may represent a
key factor for its beneﬁcial eﬀect in PSC. Little is known
about biliary enrichment in patients with PSC and its
correlation with eﬀects on liver biochemistries and the
progression of disease. In a prior study designed to
determine the optimal dose of UDCA with respect to
its biliary enrichment in PSC, biliary bile acid composi-
tion was determined in 56 patients with PSC including
30 patients with repeat bile samples treated with various
doses of UDCA. Based on their ﬁndings, the authors
concluded that biliary enrichment of UDCA increases
with increasing dose and reaches a plateau at 22–
25 mg/kg/day, with minimal additional biliary enrich-
ment at higher doses [17].
In this study, Cullen et al. [1] demonstrate in a dose–
response study that higher doses of UDCA (30 mg/kg)
lead to further improvement of liver biochemistries com-
pared to the so called ‘‘standard” doses of 20 mg/kg and
lower doses of UDCA (10 mg/kg) in PSC. Furthermore,
the authors show signiﬁcant dose–response of UDCA
bile enrichment across low, standard and high dose
groups, with no evidence for the previously described
plateau in bile enrichment after daily doses beyond
25 mg/kg. This study seems to ﬁnally prove that the con-
cept ‘‘the higher, the better”, applies to UDCA in the
treatment of PSC.
The evaluation of potential beneﬁcial eﬀects of ther-
apy in chronic liver diseases such as PSC is challenging.
The main issues include the very slow progression ofliver ﬁbrosis and the diﬃculties related to the quantiﬁca-
tion of disease progression during clinical studies and in
clinical practice. Monitoring by means of serial liver
biopsies is still considered the gold standard to monitor
progression of liver ﬁbrosis, but known shortcomings
include slow progression of ﬁbrosis, sampling error, cat-
egorical staging systems, subjective interpretation, and
potential serious adverse eﬀects from an invasive proce-
dure [18]. Cullen et al. [1] also report lack of signiﬁcant
changes in liver histology among the three groups over
the study period, which, not surprisingly, were mostly
unchanged after the short period of UDCA administra-
tion when compared to baseline. Due to the prolonged
clinical course of PSC, clinical studies with endpoints
such as death or need for transplantation require a large
number of patients and several years of follow-up, and
are expensive and time-consuming. In clinical practice,
disease progression and prognosis of PSC can be estab-
lished over time by tracking serum bilirubin, alkaline
phosphatase and/or the composite Mayo risk score
(MRS), which is calculated based on measurements of
serum bilirubin, AST, and albumin; the age of the
patient and the presence of variceal bleeding [19]. Cullen
et al. [1] found a signiﬁcant improvement in MRS com-
pared to baseline values occurred after the administra-
tion of UDCA, and, interestingly, greater reductions
were noted in the group of patients who received the
higher doses of UDCA. Surrogate endpoints derived
from combined results of clinical, biochemical, or other
laboratory assays, such as the MRS, could theoretically
be used to measure important treatment eﬀects with
great precision over a much shorter period and therefore
facilitate the conduct of smaller studies. The use of sur-
rogate endpoints of disease progression and survival in
PSC has been well-described previously [19–24], but
the degree to which surrogate markers can simulate
more deﬁnitive endpoints, such as survival free of trans-
plantation, has not yet been established. While encour-
aging, the authors’ interpretation ‘‘the survival
probability improved by the end of the study” needs
to be read with caution.
Even though UDCA is a very safe and well-tolerated
medication, higher daily doses may, in theory, be associ-
ated with a higher rate of adverse events, particularly in
the subset of patients with PSC who also have inﬂamma-
tory bowel disease. An important result of this study is
that, despite administration of daily doses of up to
44 mg/kg in the high dose group (median dose 33 mg/
kg), UDCA was not associated with exacerbation of
diarrhea in these patients and there was no signiﬁcant
diﬀerence in the side eﬀect proﬁle between the three
treatment arms, conﬁrming ﬁndings of previous studies.
A deﬁnite answer about the eﬃcacy of high dose
UDCA in PSC is needed but is not provided in this cur-
rent study. A trial with a large number of participants
and long duration is required to establish whether the
694 M.G. Silveira, K.D. Lindor / Journal of Hepatology 48 (2008) 692–694eﬀect of high dose UDCA on liver biochemistry, Mayo
risk score, histology, and cholangiography in patients
with PSC is translated into improved long-term survival.
Hopefully, the large, multicenter, National Institutes of
Health sponsored randomised trial of high dose UDCA,
currently underway, will provide such answers.References
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